News & Updates

Delayed intake of a progestogen-only pill (POP) or missing one pill does not necessarily reduce its theoretical contraceptive protection, with little effect on cervical mucus and ovulation, as shown in a study.

In the phase III SPRINTER trial, inhaled interferon-beta-1a (IFN-β1a) showed encouraging signals for preventing disease progression or death in hospitalized COVID-19 patients.

In the interim analysis of the ongoing phase III ALLEGRO-LT trial, the investigational oral JAK3*/TEC inhibitor ritlecitinib demonstrated long-term safety and remarkable scalp hair regrowth in adults and adolescents with alopecia areata (AA).

Treatment with remibrutinib, a novel oral inhibitor of Bruton’s tyrosine kinase, appears to be both safe and effective for the treatment of chronic spontaneous urticaria, a new study has found.

A smoking cessation intervention delivered via telephone resulted in greater smoking cessation rates than usual care among individuals enrolled in targeted lung health screening, according to results of the QuLIT*2 study from the UK presented at ERS 2022.

Treatment with bimekizumab for up to 2 years appears to be tolerated well in patients with moderate-to-severe plaque psoriasis, with no increased risk of adverse events (AEs) aside from a higher frequency of mild-to-moderate oral candidiasis, according to pooled analyses of data from eight randomized controlled trials (RCTs).

Extended duration perioperative thromboprophylaxis with low molecular weight heparin tinzaparin (administered before and for 56 days after surgery) does not lead to longer disease-free survival at 3 years in patients with localized invasive colorectal cancer undergoing surgical resection, reports a study.